During this week’s European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, Spain, a research team presented findings from a phase 3 trial of Samsung Bioepis' SB8, a proposed bevacizumab biosimilar referencing Avastin.
During this week’s European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, Spain, a research team presented findings from a phase 3 trial of Samsung Bioepis’ SB8, a proposed bevacizumab biosimilar referencing Avastin.
The study compared the efficacy, safety, pharmacokinetics, and immunogenicity of SB8 to the reference in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).
In total, 379 patients were randomized to receive the proposed biosimilar together with paclitaxel and carboplatin every 3 weeks, and 384 were randomized to receive the reference bevacizumab together with the same chemotherapy combination.
Treatment was followed by biosimilar or reference bevacizumab maintenance therapy until disease progression, unacceptable toxicity, death, or 1 year from randomization of the last patient. Baseline characteristics between the patients were well balanced.
The study’s primary endpoint was the best overall response rate (ORR) by 24 weeks of chemotherapy. The risk ratio (RR) was analyzed in the full analysis set (FAS), and the risk difference (RD) was analyzed in the per-protocol set (PPS).
In the FAS, the best ORR was 47.6% in the biosimilar arm versus 42.8% in the reference arm. The RR was 1.11 (95% CI, 0.975-1.269), which fell within the prespecified equivalence margin of 0.737-1.357.
In the PPS, the best ORR was 50.1% in the biosimilar arm and 44.8% in the reference arm. The RD was 5.3% (95% CI, −2.2% to 12.9%). The lower margin was contained within the prespecified equivalence margin of −12.5% to 12.5%, but the upper margin fell outside of this margin.
Median progression-free survival was 8.50 months in the biosimilar arm versus 7.90 months in the reference arm; median overall survival was 14.90 months in the biosimilar arm versus 15.80 months in the reference arm, and median duration of response was 5.60 months in the biosimilar arm versus 5.85 months in the reference arm.
The overall incidence of treatment-emergent adverse events (TEAEs) was comparable between arms, at 92.1% in the biosimilar arm and 91.1% in the reference arm. The most frequently reported TEAEs were alopecia, anemia, and nausea.
Pharmacokinetic parameters, as well as the incidence of antidrug antibodies, were comparable in the 2 treatment arms.
According to the researchers, this study demonstrated equivalence between the proposed biosimilar and its reference in terms of the best ORR risk ratio in patients with NSCLC.
Samsung Bioepis now awaits regulatory action on its marketing authorization application for the biosimilar, which it submitted to the European Medicines Agency for review in July 2019.
Reference
Reck M, et al. A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC. Presented at: European Society for Medical Oncology Congress 2019; September 27 to October 1, 2019; Barcelona, Spain. Abstract 1565P.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
New Year, New Hurdles: What's in Store for Biosimilars in 2023
December 18th 2022On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.